That's how I read it.
"The study recruited 30 patients with newly diagnosed glioblastoma and
unmethylated MGMT promotor status, a genetic profile which confers primary
resistance to temozolomide, the only existing FDA-approved drug treatment for first
line treatment."
Ann: Kazia releases final data from P2 paxalisib trial, page-13
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)